Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients

Abstract Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, association between levels, clinical symptoms, disease phase in these have not yet been fully defined. Confirmed their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load serology analysis every ten days. A total of 1334 serum samples collected from 135 analyzed using three assays for IgG-N, IgG-S IgM antibodies. Of study participants, 97% seropositive during study, two distinct clusters identified. These significantly different inflammatory related symptoms. Peak was 40.0 AU/ml non-inflammatory cluster 71.5 (P = 0.006), whereas IgG-N peaks 4.3 5.87 0.023) respectively. Finally, decision tree model designed to predict based on serological titer had an overall accuracy 80.7%. specific profile seroconversion decay antibodies can be used time-course acute infection.